7 European Projects Found
Searched on 125080 European Projects
FINISHED
Optimizing a deployable high efficacy malaria vaccine (OptiMalVax)
Start date: Jan 1, 2017, End date: Dec 31, 2021,
A highly effective malaria vaccine against Plasmodium falciparum should help prevent half a million deaths from malaria each year. New vaccine technologies and antigen discovery approaches now make accelerated design and development of a highly effective multi-antigen multi-stage subunit vaccine feasible. Leading malariologists, vaccine researchers and product developers will here collaborate in ...
Read Project
17
Partners Participants
FINISHED
European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates (EHVA)
Start date: Jan 1, 2016, End date: Dec 31, 2020,
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the Eur ...
Read Project
43
Partners Participants
FINISHED
Training network providing cutting-EDGE knowlEDGE on Herpes Virology and Immunology (EDGE)
Start date: May 1, 2016, End date: Apr 30, 2020,
Herpesviruses are widely spread, and cause life-long infections. Most individuals carry multiple herpesviruses, which can cause severe diseases, especially in children, immunocompromised individuals, and elderly. There are currently no safe vaccines against herpesvirus infections and current treatments are not satisfactory. With new insights into the molecular basis for diseases caused by immunode ...
Read Project
9
Partners Participants
FINISHED
Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection (FLUCOP)
Start date: Mar 1, 2015, End date: Feb 29, 2020,
Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Influenza infections affect all age groups but children and adults over the age of 65 are at most risk of developing severe disease.Vaccination is the most effective approach to reduce the impact of annual influenza outbreaks and potential pandemics, however, the ...
Read Project
26
Partners Participants
FINISHED
Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE)
Start date: Oct 1, 2013, End date: Sep 30, 2018,
Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to rapidly provide robust data on vaccine benefits and risks to support accelerated decision-making.Approach: To achieve this vision through a public-private partnership, ADVANCE partners 1. establish common grounds and rules for collaboration between public and ...
Read Project
30
Partners Participants
FINISHED
Adenovirus Vector Technology: Next Generation Systems for Medical Therapy (AD-VEC)
Start date: Mar 1, 2013, End date: Feb 28, 2017,
We propose a programme (AD-VEC) involving two industrial and three academic partners with the aim to identify new adenoviral vectors as vehicles in novel medical applications for cardiovascular disease and infectious disease.This will be achieved through broad knowledge exchange between partners with complimentary and cutting edge technological and in-depth skills relating to adenovirus phylogeny, ...
Read Project
6
Partners Participants
FINISHED
ADenoViruses as novel clinical treatments (ADVANCE)
Start date: Apr 1, 2012, End date: Mar 31, 2016,
ADVance is designed to integrate 8 leading academic centres and 4 private companies under a single umbrella to create an opportunity to train young scientists in adenovirus (AdV) research. Our full partners and industrial partners represent internationally leading academic centres of excellence in key facets of research into the basic biology of AdV and their application as vectors for clinical p ...
Read Project
